Weekly Oxaliplatin and Fluorouracil for Metastatic Gastric Cancer
Author Information
Author(s): Lordick F, Lorenzen S, Stollfuss J, Vehling-Kaiser U, Kullmann F, Hentrich M, Zumschlinge R, Dietzfelbinger H, Thoedtmann J, Hennig M, Seroneit T, Bredenkamp R, Duyster J, Peschel C
Primary Institution: Technical University of Munich
Hypothesis
The study aims to assess the efficacy and safety of weekly oxaliplatin plus infusional fluorouracil and folinic acid as first-line treatment in metastatic gastric cancer.
Conclusion
The weekly FUFOX regimen is well tolerated and shows notable activity as first-line treatment in metastatic gastric cancer.
Supporting Evidence
- 54% of patients showed a response to the treatment.
- Median overall survival was 11.4 months.
- Median time to progression was 6.5 months.
- 67% of patients experienced mild sensory neuropathy.
Takeaway
Doctors tested a new medicine combination to help people with stomach cancer, and it worked well for many patients.
Methodology
Patients with untreated metastatic gastric cancer received oxaliplatin and 5-FU/FA weekly for treatment, and their responses were evaluated according to RECIST criteria.
Potential Biases
Patient selection bias may have influenced the results.
Limitations
The study was nonrandomized and open-label, which may introduce bias.
Participant Demographics
Median age was 62 years; 81% were male and 19% were female.
Statistical Information
P-Value
0.001
Confidence Interval
95% CI, 39–69%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website